Trivalent Influenza Vaccine
Influenza
National Institute of Allergy and Infectious Diseases (NIAID)vaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Influenza cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vaxigrip Medical University of Warsaw | Phase 4 | BB |
Oseltamivir The University of Hong Kong | Phase 3 | BB |
Dfn-15 The University of Hong Kong | Phase 3 | B |
Trivalent Baculovirus-Expressed Influenza Ha Vaccine National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | B |
Fluzone Yale University | Phase 2 | B |
View all 9 →
Same molecule, other indications
Trivalent Influenza Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →